Memphis facility to make gene-editing treatment for sickle cell
In late 2022, Charles River completed an expansion project that increased clean room manufacturing capacity in Memphis by more than 50%. (Patrick Lantrip/The Daily Memphian file)
Boston-based Charles River Laboratories manufactures clinical and commercial cell and gene-modified cell therapies at its Shelby Drive facility.
Topics
Sickle Cell Disease Charles River Laboratories biotechAisling Mäki
Aisling Mäki has spent the better part of two decades writing about Memphis. A former digital journalist for WMC Action News 5 and staff reporter for Memphis Daily News, her work has also appeared in The Commercial Appeal, High Ground News, I Love Memphis, Inside Memphis Business, The Memphis Flyer, Memphis Parent, Memphis Magazine and Tri-State Defender.
Want to comment on our stories or respond to others? Join the conversation by subscribing now. Only paid subscribers can add their thoughts or upvote/downvote comments. Our commenting policy can be viewed here.